LLY

1,011.12

+1.64%↑

JNJ

229.43

+0.85%↑

ABBV

207.16

-1.57%↓

UNH

399.42

+1.64%↑

AZN

186

+0.19%↑

LLY

1,011.12

+1.64%↑

JNJ

229.43

+0.85%↑

ABBV

207.16

-1.57%↓

UNH

399.42

+1.64%↑

AZN

186

+0.19%↑

LLY

1,011.12

+1.64%↑

JNJ

229.43

+0.85%↑

ABBV

207.16

-1.57%↓

UNH

399.42

+1.64%↑

AZN

186

+0.19%↑

LLY

1,011.12

+1.64%↑

JNJ

229.43

+0.85%↑

ABBV

207.16

-1.57%↓

UNH

399.42

+1.64%↑

AZN

186

+0.19%↑

LLY

1,011.12

+1.64%↑

JNJ

229.43

+0.85%↑

ABBV

207.16

-1.57%↓

UNH

399.42

+1.64%↑

AZN

186

+0.19%↑

Accueil・Liste d'Actions・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Ouvert

4.13 0.98

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

4.05

Max

4.26

Chiffres clés
By Trading Economics
Revenu	-8.5M -35M
Employés	106
EBITDA	-11M -37M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+99.28% upside

Dividendes
By Dow Jones
Prochains Résultats	19 mai 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	126M 290M
Ouverture précédente	3.15
Clôture précédente	4.13

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

1.23 / 1.45 Support & Résistance

Zentalis Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

12 mai 2026, 22:50 UTC

Résultats

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12 mai 2026, 22:49 UTC

Résultats

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12 mai 2026, 22:32 UTC

Résultats

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12 mai 2026, 23:48 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12 mai 2026, 22:57 UTC

Market Talk

Résultats

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12 mai 2026, 22:26 UTC

Résultats

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12 mai 2026, 22:25 UTC

Résultats

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12 mai 2026, 22:25 UTC

Résultats

Aristocrat Leisure Interim Dividend A$0.50/Security

12 mai 2026, 22:24 UTC

Résultats

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12 mai 2026, 22:23 UTC

Résultats

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12 mai 2026, 22:23 UTC

Résultats

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12 mai 2026, 22:19 UTC

Résultats

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12 mai 2026, 22:14 UTC

Résultats

CBA: Business Lending Continued to Grow Above System>CBA.AU

12 mai 2026, 22:14 UTC

Résultats

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12 mai 2026, 22:13 UTC

Résultats

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12 mai 2026, 22:12 UTC

Résultats

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12 mai 2026, 22:12 UTC

Résultats

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12 mai 2026, 22:11 UTC

Résultats

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12 mai 2026, 22:11 UTC

Résultats

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12 mai 2026, 22:10 UTC

Résultats

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12 mai 2026, 22:09 UTC

Résultats

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12 mai 2026, 22:09 UTC

Résultats

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12 mai 2026, 22:08 UTC

Résultats

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12 mai 2026, 22:07 UTC

Résultats

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12 mai 2026, 22:06 UTC

Résultats

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12 mai 2026, 22:06 UTC

Résultats

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12 mai 2026, 22:05 UTC

Résultats

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12 mai 2026, 22:04 UTC

Résultats

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12 mai 2026, 22:04 UTC

Résultats

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12 mai 2026, 22:04 UTC

Résultats

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Comparaison

Variation de prix

Zentalis Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

99.28% hausse

Prévisions sur 12 Mois

Moyen 8.25 USD 99.28%

Haut 10 USD

Bas 4 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

5 ratings

Achat

Maintien

Vente

Basé sur 5 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

1.23 / 1.45Support & Résistance

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

There is one bearish event.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.